Disease Information & Support

www.lls.org/diseaseinformation

The Word:

donate

Generic name Omacetaxine mepesuccinate
Pronunciation OH-ma-set-AX-een MEP-i-SUX-in-ate
Brand name(s), other common name(s) Synribo®
Drug type  Antineoplastic
How the drug is given Subcutaneous (SC) injection

Omacetaxine mepesuccinate is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).

The effectiveness of omacetaxine mepesuccinate was evaluated using a combined group of patients whose cancer progressed after previous treatment with two or more TKIs. All participants were treated with omacetaxine mepesuccinate.

Side effects needing medical attention: Low platelet counts, low red blood cell counts, low white blood cell counts, low level of lymphocytes, diarrhea, nausea, fatigue, weakness, injection site reaction, fever, infection, febrile neutropenia, constipation, vomiting, upper abdominal pain, peripheral edema, joint pain, pain in extremity, back pain, headache, insomnia, cough, nose bleed, hair loss, rash. 

 

For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Monday, December 30, 2013